SOMERVILLE, N.J., March 6, 2023 (Newswire.com)
-
Spectral Design & Test Inc (SDT) today announced that they have successfully characterized and verified 12 Memory Compilers (configurable Memory Designs) in 14/22 nm process nodes using their proprietary "SimLess" technology to capture design specific data models. The ML/AI based Software complements MemoryTime, the resulting methodology was able to cut the compute budget for analysis and characterization of Memory Compilers plus a significant improvement in data integrity.
Characterization in advanced process nodes involves running exhaustive simulations by using circuit analysis tools to build robust designs. "Based upon data from over 50 designs across various process nodes, SDT engineers used a learning system to train a data model to accurately represent SRAM timing, leakage, power as a surface over a wide range of Memory Compiler configurations," said Deepak Mehta, President & CEO at Spectral. "Furthermore, the inference-based data model self-adjusts by using 'SimLess' to adjust the surface (see Fig 1/Fig 2) such that final PPA (Performance Power Area) metrics are within 1-3 percent accuracy. A combination of datapoints and curve fit driven 3-D surface and targeted spice simulation ensures true to silicon outcome ensuring a high level of data integrity.
MemoryTime is SDT's Memory Characterization & Analysis tool, "Simless" data model is compatible with Verilog Models generated by MemoryTime. "Simless" executable will be rolled out in April and will be demonstrated at our Booth in GOMAC 2023.
About Spectral Design & Test, Inc.
Spectral is a point solution provider specialized in embedded memory development. Our products address the needs of library developers & SOC designers. Spectral also offers intellectual property (IP) in the form of specialized embedded memories as part of their MemoryIP™ offering. Spectral currently supports customers in several different markets namely medical, IoT, 5G, Mil-Aero and many others. For more information, visit http://www.spectral-dt.com or email us at [email protected]
Contact Information:
Michael Walton
Vice President Marketing [email protected]
2146322427
According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.
LAS VEGAS, March 20, 2023 (Newswire.com)
-
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson's disease. China is an increasingly important pharmaceutical market with cultural acceptance of plant-based formulations, which is a good fit for Gb Sciences' drug candidates. Gb Sciences' first international patent also confirms that the Company's intellectual property strategy can work globally and strengthens the Company's patent portfolio. The global market for treatments of Parkinson's disease is projected to grow to $8.8 billion by the year 2026, and new therapies to address Parkinson's disease symptoms are greatly needed.
"The issuance of Gb Sciences' first international patent protecting methods of using our proprietary cannabinoid-containing formulations for treating Parkinson's disease is an important milestone in the development of these vitally important therapies. Gb Sciences' recent patent issued in China validates both our plant-inspired drug discovery process and intellectual property strategy, which involve defining and protecting Minimum Essential Mixtures," explained Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences, Inc. "Gb Sciences starts its drug discovery process with plant-based therapies that are working anecdotally or in traditional medical systems, then we systematically reduce the number of compounds to reveal Minimum Essential Mixtures. Gb Sciences' novel Minimum Essential Mixtures retain the increased efficacy of whole plant medicines, but they are easier to manufacture with precision at scale like single ingredient drugs. These Minimum Essential Mixtures are a viable alternative to standard single ingredient drugs or traditional whole plant medicines."
Gb Sciences' Minimum Essential Mixture-based drug development strategy does not aim to treat complex diseases as if they were caused by a single factor, but instead addresses the combination of factors that lead to a complex human disorder. Minimum Essential Mixtures (MEMs) are potentially more effective than single ingredient drugs because the different active ingredients target the multiple human processes responsible for complex diseases, such as neurodegeneration, heart disease, and cancers. As such, MEMs may offer a more holistic treatment for complex disorders such as Parkinson's disease that cannot be attributed to a single cause, while maintaining the manufacturing and quality control advantages of single ingredient drugs.
Gb Sciences' patent portfolio currently contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications that cover our novel AI-enabled drug discovery platform and proprietary plant-inspired therapies for more than 65 different disorders.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
